Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
Methylmalonic aciduria cblB type is an autosomal recessive disorder caused by biallelic variants in MMAB encoding mitochondrial ATP:cob(I)alamin adenosyltransferase. Affected individuals present in infancy with metabolic decompensation, elevated methylmalonic acid, and mitochondrial dysfunction due to impaired adenosylcobalamin synthesis and methylmalonyl-CoA mutase activity.
Genetic evidence includes 35 cblB patients with 19 distinct MMAB mutations (PMID:16410054) and 97 individuals harboring bi-allelic variants across 33 recurrent and 16 novel alleles (PMID:34796408). Segregation in at least six affected siblings across three families supports autosomal recessive inheritance (two siblings in an iPSC study [PMID:29660608]; two sibling pairs in a mitochondrial study [PMID:24813872]).
The variant spectrum comprises missense, nonsense, splice-site, and frameshift changes, with pathogenic alleles clustering in exon 7. Notable examples include c.287T>C (p.Ile96Thr) and recurrent founder variants p.Arg186Trp and p.Arg191Trp, none detected in controls (PMID:16410054; PMID:34796408).
Functional assays reveal that destabilizing missense mutations and truncating variants abolish ATR stability and enzymatic activity, increase reactive oxygen species, impair mitochondrial respiration, and recapitulate patient fibroblast phenotypes (PMID:24813872; PMID:20556797). Pharmacological chaperones restore stability and activity of the p.Ile96Thr mutant in vitro and in mouse liver and brain, confirming a loss-of-function mechanism responsive to targeted therapy (PMID:23674520).
Collectively, robust genetic, segregation, and experimental data justify a Definitive ClinGen classification for the MMAB–methylmalonic aciduria, cblB type association, with Strong genetic and Strong functional evidence. MMAB sequencing is essential for accurate diagnosis, family counseling, and implementation of precision therapies in cblB patients.
Gene–Disease AssociationDefinitiveOver 132 probands across independent cohorts with multi-family segregation and concordant functional data Genetic EvidenceStrong132 probands, comprising 35 cblB patients and 97 individuals with bi-allelic MMAB variants, with segregation in three families Functional EvidenceStrongBiochemical assays, patient fibroblasts, iPSC and mouse models, and pharmacological rescue confirm loss-of-function mechanism |